Analysts think QNCX stock price could increase by 522%
Apr 06, 2025, 11:25 AM
-0.81%
What does QNCX do
Quince Therapeutics, based in South San Francisco, develops therapeutics using its AIDE technology to encapsulate drugs in patients' red blood cells, targeting rare diseases like Ataxia-Telangiectasia. The company went public on May 9, 2019, and employs 32 people.
6 analysts think QNCX stock price will increase by 521.95%. The current median analyst target is $7.65 compared to a current stock price of $1.23. The lowest analysts target is $4.04 and the highest analyst target is $10.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
